Browse the evidence

GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) induce significant weight loss (14.9%–20.9%) and improve fertility in obese individuals, particularly those with PCOS, by acting on hypothalamic and brainstem regions to suppress appetite and stimulate GnRH/LH release.

GLP-1 agonists like semaglutide and tirzepatide are highly effective for significant weight loss and can improve fertility in obese individuals, especially those with PCOS. However, they come with high rates of gastrointestinal side effects and weight regain upon discontinuation. They should be used under medical supervision, with careful attention to dosing and long-term management strategies.

Strategies to minimize muscle loss during GLP-1 therapy include increasing protein intake to ≥1.2 g/kg/day and engaging in resistance training 2-3 times per week.

To keep your muscles while losing weight on these drugs, eat at least 1.2 grams of protein per kilogram of your body weight every day. Also, lift weights or do resistance exercises 2-3 times a week. This combination helps protect your strength and metabolic rate.

Combining GLP-1 receptor agonists with structured exercise (specifically resistance training) mitigates the loss of lean body mass associated with pharmacological weight loss, whereas GLP-1 agonists alone result in significant lean mass loss.

If you are on a GLP-1 medication like semaglutide or tirzepatide, you must incorporate resistance training (2-3 times per week) into your routine. The medication will cause you to lose muscle along with fat (up to 40% of weight loss). Resistance training preserves this muscle, maintaining your metabolism and strength. Combine this with moderate aerobic activity (150 mins/week) and adequate protein intake for the best long-term results.

Weekly tirzepatide injections combined with dietician support reduce OSA severity by approximately 50% in obese patients with moderate to severe OSA.

If you are obese and have moderate to severe sleep apnea, ask your doctor about tirzepatide. This weekly injection, combined with dietary support, has been shown to cut your apnea severity in half. It is FDA-cleared for this use and may improve your blood pressure and sleep quality, though you should expect some mild stomach issues initially.

Melanocortin-4 receptor (MC4R) agonists significantly reduce body weight, BMI, and hunger scores in patients with obesity, including those with rare genetic syndromes.

If you have obesity, particularly if it is linked to a rare genetic condition, MC4R agonist drugs like setmelanotide can significantly reduce your body weight, BMI, and hunger. These drugs work by activating receptors in your brain that control satiety and energy expenditure. Treatment involves daily subcutaneous injections, with doses adjusted based on your age and how well you tolerate the medication. While lifestyle changes are important, they often lead to modest and unsustainable weight loss, making these drugs a valuable option for those who struggle with conventional methods.

GLP-1 receptor agonists reduce food intake, increase satiety, delay gastric emptying, and improve glucose tolerance, leading to weight loss in humans.

GLP-1 receptor agonists are a proven, FDA-approved treatment for obesity and type 2 diabetes. They work by reducing appetite and improving metabolic function. Consult a healthcare provider to see if this treatment is appropriate for you.

Orforglipron 45 mg significantly reduces BMI, body weight, waist circumference, and HbA1c in patients with T2DM or obesity, with efficacy increasing at higher doses.

If you have T2DM or obesity, the 45 mg dose of oral orforglipron is highly effective for reducing weight and blood sugar. It works by mimicking a gut hormone to control appetite and insulin. Expect significant results, but be aware of potential side effects like nausea.

Combined treatment with structured moderate-to-vigorous exercise and GLP-1 receptor agonist (liraglutide) significantly improves physical functional performance and cardiorespiratory fitness compared to pharmacotherapy alone, whereas pharmacotherapy alone fails to improve these fitness metrics despite weight loss.

If you are using GLP-1 medication for weight loss, do not skip exercise. The medication will help you lose weight, but it will not significantly improve your stamina or physical function. To improve your ability to perform daily tasks (like climbing stairs) and your heart health, you must engage in structured moderate-to-vigorous exercise (at least 150 minutes per week). Combining the medication with exercise yields the best results for physical fitness.

Exercise alone produces similar improvements in physical functional performance and cardiorespiratory fitness as the combined treatment of exercise and GLP-1 agonist, indicating that exercise is the primary driver of fitness gains independent of the pharmacotherapy.

You do not need to take medication to get the physical fitness benefits of exercise. A structured exercise program (150+ minutes of moderate-to-vigorous activity per week) improves your stamina and functional performance just as well as combining exercise with GLP-1 medication. If you cannot or choose not to take medication, exercise remains the most effective way to improve physical fitness.

Next-generation GLP-1 based therapies (oral formulations, small-molecule agonists, multi-receptor agonists) aim to achieve greater efficacy (>25% weight loss), improved tolerability, and novel delivery platforms.

Next-generation GLP-1 based therapies aim to achieve greater weight loss (>25%), improved tolerability, and novel delivery platforms, including oral formulations and small-molecule agonists. These therapies are currently in clinical trials and represent the future direction of obesity treatment.

GLP-1 receptor agonists (liraglutide 3 mg, semaglutide 2.4 mg) and tirzepatide are effective first-line pharmacological treatments for obesity in psoriasis patients, providing significant weight loss and independent improvements in psoriasis severity (PASI scores) through anti-inflammatory mechanisms.

If you have psoriasis and obesity, GLP-1 drugs like semaglutide or tirzepatide are highly effective first-line treatments. They help you lose significant weight and can directly reduce your psoriasis severity, not just through weight loss but by lowering inflammation. Start with lifestyle changes, but if you need medication, these drugs are safe and effective. Work with your doctor to find the right dose and manage any initial stomach side effects by starting low and going slow.

GLP-1 receptor agonists (GLP1RAs) such as semaglutide and liraglutide induce significant weight loss (5-15%) and improve metabolic markers by delaying gastric emptying, suppressing appetite via central nervous system signaling, and enhancing glucose-dependent insulin secretion.

GLP-1 medications like semaglutide and liraglutide are highly effective for weight loss (5-22%) and metabolic health. They work by slowing digestion and signaling fullness to the brain. Start with the lowest dose to minimize nausea, which usually improves over time. Combine with a calorie-controlled diet and exercise for best results. Oral versions exist but may have different absorption requirements.

Significant weight loss (≥15% body weight) achieved through intensive dietary intervention can induce remission of type 2 diabetes in a majority of patients.

To potentially reverse Type 2 Diabetes, you must lose a significant amount of weight—specifically 15% or more of your body weight. This usually requires a structured, intensive dietary intervention (like total diet replacement) under medical supervision, not just 'eating less'. The goal is to remove fat from your liver and pancreas to restore their normal function.

Tirzepatide (5, 10, and 15 mg) is a cost-effective treatment for weight management compared to liraglutide in the UK, demonstrating dominance (cost savings and QALY gains) in the general obesity trial population and favorable ICERs in the specific NICE-reimbursed population.

For patients in the UK with obesity or overweight plus complications, tirzepatide (5, 10, or 15 mg weekly) combined with diet and exercise is a cost-effective treatment option compared to liraglutide. It offers potential cost savings and quality-of-life gains, and unlike liraglutide which is restricted to specialist services, tirzepatide can be prescribed in primary care.

Tirzepatide reduces the incidence of obesity-related complications, specifically knee replacements (29-46% reduction) and type 2 diabetes (25-48% reduction), compared to liraglutide.

Tirzepatide treatment is associated with significantly lower rates of knee replacements and type 2 diabetes compared to liraglutide, likely due to greater weight loss and prediabetes reversal.

Dual incretin agonists (e.g., tirzepatide) and newer GLP-1 receptor agonists (e.g., semaglutide) provide superior glycaemic control and greater weight reduction compared to earlier GLP-1 agents.

If you have Type 2 Diabetes, newer injectable medications like tirzepatide or semaglutide are significantly more effective at lowering blood sugar and reducing weight than older GLP-1 drugs. Discuss these options with your doctor, especially if you are struggling with weight or glucose control despite previous treatments.

Continuous Glucose Monitoring (CGM) significantly improves glycaemic outcomes in Type 2 Diabetes patients compared to standard self-monitoring.

Using a Continuous Glucose Monitor (CGM) can help you manage Type 2 Diabetes more effectively than traditional finger-prick tests. Studies show it can lower your average blood sugar (HbA1c) by 0.5-1.0%. While cost and insurance coverage can be hurdles, the real-time feedback helps you make better daily choices.

Long-acting GLP-1 receptor agonists (semaglutide and dulaglutide) provide superior efficacy, particularly in cardio-renal protection, and overall value compared to other long-acting GLP-1RAs in China, earning strong clinical recommendations.

For patients with Type 2 Diabetes in China, Semaglutide and Dulaglutide are the preferred long-acting GLP-1 receptor agonists. They offer strong recommendations due to superior efficacy, particularly in protecting the heart and kidneys, and better overall value. While newer drugs like Tirzepatide show great potential for weight loss and glucose control, their high cost and lack of insurance coverage make them less accessible. Patients should discuss these options with their doctors, prioritizing agents with established cardiovascular benefits and insurance coverage.

Treatment with tirzepatide (10-15 mg weekly) causes significant shifts to lower BMI categories in adults with obesity, which is associated with substantial improvements in cardiometabolic risk factors including blood pressure, fasting insulin, and lipid profiles.

If you have obesity or overweight with related health issues like high blood pressure or high cholesterol, talk to your doctor about tirzepatide. It is a once-weekly injection that helps many people move to a lower BMI category, which is linked to better heart health and metabolic markers. It works best when combined with a reduced-calorie diet and increased physical activity.

Micellar casein (MC) consumed at sahur partially mitigates fasting-induced declines in anaerobic power (Wingate peak and mean power) and upper-body strength (bench press) in combat sport athletes during Ramadan, outperforming whey protein isolate and placebo.

If you are fasting for 11+ hours (like during Ramadan) and competing in anaerobic sports, take 0.4g/kg of Micellar Casein with your pre-dawn meal. This slow-digesting protein helps maintain your power output better than Whey Protein or no protein, though it won't fully restore you to fed-state levels.

Prioritizing protein intake maximizes the Thermic Effect of Food (TEF), thereby increasing total energy expenditure compared to high-fat or high-carbohydrate diets at equal caloric levels.

To burn more calories through digestion, prioritize protein in your meals. Protein has a much higher thermic effect (20-30%) compared to fat (2-5%) and carbs (5-15%). This means you burn more energy just processing protein-rich foods.

Weight loss achieved through caloric restriction, exercise, or bariatric surgery reduces the Apnea-Hypopnea Index (AHI) in patients with Obstructive Sleep Apnea (OSA) and Obesity Hypoventilation Syndrome (OHS), with the magnitude of AHI reduction correlating non-linearly with the percentage of BMI reduction.

Losing weight is one of the most effective ways to reduce the severity of sleep apnea. You do not need to reach a 'perfect' weight to see benefits; even a 10% reduction in body weight can significantly lower the number of breathing interruptions during sleep. If lifestyle changes (diet and exercise) do not show improvement in your sleep metrics within 3 months, consult your doctor about escalating to pharmacotherapy (like GLP-1 agonists) or bariatric surgery, which can induce remission in many cases.

Replacing 5% of total energy intake from saturated fatty acids (SFAs) with either monounsaturated (MUFAs) or polyunsaturated fatty acids (PUFAs) is associated with a statistically significant reduction in overall mortality risk.

To lower your risk of death, swap 5% of your daily calories from saturated fats (found in red meat, butter, full-fat dairy) for unsaturated fats (found in olive oil, nuts, seeds, fish). You do not need to eat less food; just change the source of the fat. For example, if you usually use butter on toast, switch to olive oil or avocado spread. This simple swap is linked to a 12-13% lower risk of mortality.

Higher intake of Polyunsaturated Fatty Acids (PUFAs) is associated with a reduced risk of overall mortality, whereas Saturated Fatty Acid (SFA) intake is positively associated with increased mortality risk.

Increase your intake of Polyunsaturated Fats (PUFAs) by eating more fatty fish (like salmon, mackerel), walnuts, and seeds. Simultaneously, reduce your intake of Saturated Fats (SFAs) found in red meat and full-fat dairy. This shift is associated with a lower risk of death.